These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6861157)

  • 1. Tamoxifen-induced fluorescence as a marker of human breast tumor cell responsiveness to hormonal manipulations: correlation with progesterone receptor content and ultrastructural alterations.
    Mouriquand J; Jacrot M; Louis J; Mermet MA; Saez S; Sage JC; Mouriquand C
    Cancer Res; 1983 Aug; 43(8):3948-54. PubMed ID: 6861157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ultrastructural study of rat mammary tumors and human breast cancer cells following treatment with tamoxifen].
    Kamioki S
    Gan No Rinsho; 1986 Nov; 32(14):1809-18. PubMed ID: 3099030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tamoxifen induced fluorescence as a marker of hormone receptors: cytological study of fine needle biopsy of malignant breast tumors in treated women].
    Mouriquand J; Mouriquand C; Sage JC; Saez S; Jacrot M; Gabelle P
    C R Seances Acad Sci III; 1981 Dec; 293(15):801-6. PubMed ID: 6804016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
    Lundgren S; Søreide JA; Lea OA
    Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen.
    Murphy LC; Niu Y; Snell L; Watson P
    Clin Cancer Res; 2004 Sep; 10(17):5902-6. PubMed ID: 15355923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormonal therapy of endometrial cancer].
    Kato J
    Gan No Rinsho; 1985 Jul; 31(9 Suppl):1182-8. PubMed ID: 4057575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro.
    Lazo JS; Schwartz PE; MacLusky NJ; Labaree DC; Eisenfeld AJ
    Cancer Res; 1984 Jun; 44(6):2265-71. PubMed ID: 6722767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
    Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
    Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.
    Kopp A; Jonat W; Schmahl M; Knabbe C
    Cancer Res; 1995 Oct; 55(20):4512-5. PubMed ID: 7553618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
    Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
    Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
    Namer M; Lalanne C; Baulieu EE
    Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.